Daewoong Holds Symposium to Commemorate Launch of 36th Domestic New Drug 'Enblo'

Daewoong Pharmaceutical announced on the 7th that it held the launch symposium "ENVLO-D" for "Envlo" (active ingredient: Inavogliflozin), the 36th domestic new drug developed as a treatment for type 2 diabetes, on the 3rd at the Shilla Hotel in Jung-gu, Seoul, and Raonjena in Daegu. About 200 medical professionals attended in person and about 280 participated online, creating a lively atmosphere.

On the 3rd, at the Shilla Hotel in Jung-gu, Seoul, Professor Lim Soo from Bundang Seoul National University Hospital is presenting on the advent of SGLT-2 inhibitors and the first steps of Enblo at the Enbroad symposium commemorating the launch of Enblo.
[Photo by Daewoong Pharmaceutical]

ENVLO-D is a compound word combining Envlo and "Road," symbolizing the path forward. Envlo, the first domestic sodium-glucose co-transporter (SGLT)-2 inhibitor class diabetes treatment, represents the first step toward improving the quality of life for diabetes patients both in Korea and worldwide.

The symposium was conducted in a hybrid format with two channels: on-site and online. For the online channel, accessibility for domestic medical professionals was enhanced through webinars and the online medical professional site Doctorville.

The ENVLO-D symposium held in Seoul began with opening remarks by co-chairs Dr. Song Young-deuk, director of Song Young-deuk Endocrinology Clinic, and Professor Cha Bong-soo of Yonsei University College of Medicine Severance Hospital. The symposium consisted of sessions on ▲ the emergence of SGLT-2 inhibitors and the first step of Envlo ▲ major clinical results of Envlo and a Q&A session. In the session "The Emergence of SGLT-2 Inhibitors and the First Step of Envlo," Professor Lim Soo from Bundang Seoul National University Hospital introduced the SGLT-2 inhibitor class, which is gaining attention as the next-generation diabetes treatment, and presented the development and significance of Envlo as the first domestic SGLT-2 inhibitor new drug. Following this, in the "Major Clinical Results of Envlo" session, Professor Kim Shin-gon from Korea University Anam Hospital shared the results of phase 3 clinical trials of Envlo, including combination therapy and subgroup analyses.

Envlo tablets, belonging to the SGLT-2 inhibitor class, demonstrated equivalent efficacy with only 0.3 mg, less than one-thirtieth of existing treatments, proving excellent blood sugar-lowering effects and safety. Based on strengths such as ▲ approximately 1% reduction in glycated hemoglobin compared to placebo, ▲ a high target blood sugar achievement rate of about 70% (HbA1c<7%), and ▲ improvements in cardiovascular risk factors including weight, blood pressure, and lipids, Envlo is planned to establish itself as the next blockbuster domestic new drug in the diabetes treatment market.

Professor Cha Bong-soo said, "With the expansion of reimbursement for diabetes drug classes, I believe the SGLT-2 inhibitor market will also experience significant growth. As the first domestic SGLT-2 inhibitor, there are high expectations for Envlo's role in the market," sharing his impressions of participating in the symposium.

The event was simultaneously held in Daegu. The symposium, which began with opening remarks by Won Kyu-jang, president of the Korean Diabetes Association and professor at Yeungnam University College of Medicine, and Ha Seung-woo, vice president of the Korean Diabetes Association and director of Ha Seung-woo Internal Medicine Clinic, featured presentations by Professor Kim Mi-kyung of Keimyung University College of Medicine and Professor Moon Jun-sung of Yeungnam University College of Medicine on the prospects of SGLT-2 inhibitors and the significance of Envlo's launch. Professor Won Kyu-jang stated, "The positive effects observed in clinical trials conducted on Koreans provide reliable support when prescribing to actual patients," and congratulated the launch of the domestic new drug.

Daewoong Pharmaceutical plans to continue holding events in more than 20 cities nationwide following this launch symposium.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "We are pleased that the launch of Envlo serves as a cornerstone for strengthening competitiveness in the pharmaceutical and bio industries, which are future growth engines of our country," adding, "We will also accelerate global expansion so that this domestic new drug contributes to improving the quality of life of diabetes patients not only in Korea but around the world."

This content was produced with the assistance of AI translation services.